Cargando…
Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry
The approval of the first small interfering RNA (siRNA) drug Patisiran by FDA in 2018 marks a new era of RNA interference (RNAi) therapeutics. MicroRNAs (miRNA), an important post-transcriptional gene regulator, are also the subject of both basic research and clinical trials. Both siRNA and miRNA mi...
Autores principales: | Wang, Peipei, Zhou, Yue, Richards, Arthur M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419061/ https://www.ncbi.nlm.nih.gov/pubmed/34522211 http://dx.doi.org/10.7150/thno.62642 |
Ejemplares similares
-
siRNA Versus miRNA as Therapeutics for Gene Silencing
por: Lam, Jenny K W, et al.
Publicado: (2015) -
Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics
por: Zare, Mina, et al.
Publicado: (2022) -
Editing independent effects of ADARs on the miRNA/siRNA pathways
por: Heale, Bret S E, et al.
Publicado: (2009) -
SUMOylation of TARBP2 regulates miRNA/siRNA efficiency
por: Chen, Cheng, et al.
Publicado: (2015) -
Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine
por: Chakraborty, Chiranjib, et al.
Publicado: (2017)